UK Biopharma Looks To Learn From Flagship Pioneering And Make ‘Bigger Leaps’
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
You may also be interested in...
Quotient Therapeutics is the fifth new start-up unveiled by Flagship this year, and will be co-located in the US and UK to tap into leading academic genomic expertise.
The two partners are committing $100m to a 10-program effort combining Pfizer’s R&D capabilities with technologies and modalities housed within Flagship Pioneering and its portfolio companies.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.